Innovative Technologies in multimarketing agreements
This article was originally published in Clinica
Innovative Technologies, a UK developer of polymer-based woundcare products, recorded turnover of £42,572 ($66,412) for the first six months ended June 30th, 1995. The company, which posted losses of £1.2 million for the period against a loss of £0.6 million in the 1994 first half, was floated on the London stock exchange in December 1994. Chairman Ronald Somerville says the company is aiming for annual woundcare sales in excess of £10 million within the next two years.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.